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progression in this and other glomerular dis-
eases [3]. In these patients, however, GFR was
still normal at follow-up and the fraction of scle-
rotic glomeruli only increased from 4% to 8%.
We did study these patients on a regular basis,
but only reported and analyzed their data from
the two time points corresponding to their renal
biopsies. We did not determine quantitative
albuminuria during the GFR clearances because
of the significant potential for variability associ-
ated with bladder emptying in each of the 20-
min collection periods. What impact did ACE
inhibitors have on our patients? This is difficult
to say, as patients often start ACE inhibitors
when they deteriorate clinically. For example,
the patient with the largest decrease in GFR and
the second largest increase in albumin creatinine
ratio was on an ACE inhibitor.
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effect of oral insulin on
residual -cell function in
type 1 diabetes
Original article:
Oral insulin administration and residual -cell
function in recent-onset type 1 diabetes: a multi-
centre randomised controlled trial. Chaillous L,
Lefèvre H, Thivolet C et al. Lancet 2000; 356: 545–9.
Summary
On the basis that oral administration of insulin
prevents autoimmune β-cell destruction in non-
obese diabetic (NOD) mice, the authors evalu-
ated the potential protection of oral insulin on
residual β-cell function in 131 autoantibody-
positive diabetic patients (age range 7–40 years)
within 2 weeks of diagnosis.
Three groups of patients were randomly
assigned 2.5 mg or 7.5 mg oral insulin daily, or
placebo, for 1 year, in addition to subcutaneous
optimized insulin therapy. Residual β-cell func-
tion was measured by serum C-peptide concen-
trations in the fasting state and after glucagon or
meal stimulation. The putative tolerizing proper-
ties of oral insulin were indirectly evaluated by
assays of autoantibodies to β-cell antigens (islet
cell, insulin, 65 kD isoform of glutamic acid 
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Fig. 1: Mean fasting, glucagon-stimulated and meal-stimulated
C-peptide concentrations in treated type 1 diabetic patients
receiving placebo, 2.5 mg or 7.5 mg oral insulin. Error bars
show SE.
decarboxylase [GAD65] and tyrosine phos-
phatase/islet antigen 2 [IA-2] antibodies).
Baseline C-peptide and HbA1c concentrations
were similar in the three groups. During follow-
up and after 1 year, the three groups did not
significantly differ in subcutaneous insulin
requirements, in HbA1c concentrations, or 
in fasting, glucagon- and meal-stimulated 
C-peptide concentrations (Fig. 1). Neither age
nor C-peptide concentration at entry influenced
treatment effects. No significant differences
appeared in the time-course of antibodies to
insulin, GAD65 or IA-2.
The authors conclude that, at the doses 
used in this trial, oral insulin initiated at clinical
onset of type 1 diabetes did not prevent or 
slow the progression of autoimmune β-cell
destruction.
Comment
Because oral tolerance closely depends on the
dose of antigen administered, it is interesting to
note that another study has evaluated the effect
of 5 mg oral insulin on residual β-cell function
in early-onset type 1 diabetes [1]. Pozzilli et al.
also failed to evidence any protective effect of
oral insulin in 80 diabetic patients treated by
intensive subcutaneous insulin therapy. More-
over, in patients younger than 15 years, a ten-
dency for lower C-peptide concentrations was
identified at 9 and 12 months after initiation of
oral insulin administration. While the results of
the Diabetes Prevention Trial of Type 1 Diabetes
(DPT-1) are expected with hope and some 
anxiety, these two well-conducted independent
studies raise some significant doubt about the
preventive efficacy of this large multinational
trial in subjects at risk for developing type 1 
diabetes.
Oral tolerance has been shown to work in
some animal models of human autoimmune dis-
eases [2]; recent studies have deciphered a num-
ber of cellular and molecular mechanisms
underlying mucosal tolerance in such models.
Those mechanisms include clonal deletion and
anergy of autoreactive T cells with large doses of
autoantigen, whereas immunosuppressive trans-
forming growth factor-β-related peptides and
active cellular suppression by regulatory T cells
can be induced by low doses. In NOD mice, 1
mg of oral porcine insulin given twice weekly is
able to prevent autoimmune diabetes and to
induce tolerance, but smaller doses do not func-
tion [3]. However, a protocol effective in one
animal model may be ineffective in another.
This is illustrated by the fact that oral insulin
does not prevent, and even exacerbates, the dia-
betogenic autoimmune process in bio-breeding
(BB) rats [4]. As recently recalled, one cannot
ignore that administration of autoantigen is able
to prime and trigger autoimmunity rather than
induce immunological tolerance [5].
Immunogenic autoantigens vs. tolerogenic 
self-antigens
Despite those negative observations, (re)pro-
gramming of the immunological self-tolerance
of islet β-cells continues to be a very rational
approach in the prevention of type 1 diabetes.
The design of the most appropriate strategy
demands a precise knowledge of the mecha-
nisms by which self-tolerance of the β-cell is
established in reality. The thymus plays a pivotal
role in T cell self-tolerance of neuroendocrine
principles [6]. Central T cell self-tolerance of
the insulin family may follow the expression of
insulin-related genes by distinct cell populations
following a clear hierarchical pattern in their rel-
ative dominance: insulin-like growth factor-2
(IGF2) by thymic epithelium > insulin-like
growth factor-1 (IGF1) by thymic macrophages
>> insulin (INS) by thymic dendritic cells
[7–11]. Other genes coding for β-cell antigens
are also expressed within the thymus cellular
network [12]. For T cells having escaped the
powerful thymic censorship, peripheral tolero-
genic mechanisms provide additional brakes for
preventing the risk of further autoimmune
responses directed to insulin-secreting β-cells.
More and more studies are documenting the
failure of thymic tolerogenic function in the
pathophysiology of autoimmunity. Recently, we
reported that the ontogenetic development of 
β-cell autoimmunity in diabetes-prone BB
(BBDP) rats might be associated with a thymus-
specific defect of Igf2 expression [12]. This 
tissue-specific Igf2 defect may contribute,
together with other genetic mechanisms, both 
to lymphopenia and absence of central self-
tolerance of the insulin hormone family in
BBDP rats [13, 14]. The molecular mechanism
responsible for the defect of Igf2 expression in
the thymus of these animals remains to be iden-
tified. However, since insulin is a specific
immunogenic β-cell autoantigen and is ineffec-
tive in protecting residual β-cell function,
the tolerogenic properties of IGF-II (or IGF-
II-derived peptides), such as the self-antigen of
the insulin family, should now be explored as
another potential means of preventing type 1
diabetes.
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Summary and Comment:
Vincent Geenen, Liège, Belgium
Persisting islet cell 
antigens in type 1 diabetes
Original article:
High frequency of persisting or increasing islet-
specific autoantibody levels after diagnosis of
type 1 diabetes presenting before 40 years of
age. Decochez K, Tits J, Coolens J-L et al. Diabetes Care
2000; 23: 838–44.
Summary
The authors investigated the presence of major
autoantibodies in 194 type 1 diabetic patients
below 40 years of age, including antibodies to
islet cell (ICA), glutamic acid decarboxylase 65
(GADA) and tyrosine phosphatase (IA-2A), at
diagnosis and during 4 years of follow-up.
The percentage of patients positive for at least
one antibody remained very high 4 years after
diagnosis (Table I), suggesting the persistence of
islet cell antigens. Two of the 14 initially anti-
body-negative patients became antibody-positive
after diagnosis. The divergent temporal patterns
of appearance of ICA, GADA and IA-2A sug-
gest that the ICA test reflects the presence of
other autoimmune processes. Finally, the num-
ber of patients with autoimmune type 1 diabetes
may be underestimated if assays with low sensi-
tivity are used. GADA assays have the best diag-
nostic sensitivity after clinical onset of the dis-
ease.
Comment
Measurement of different autoantibodies to islet
cell antigens in patients with type 1 diabetes at
diagnosis is not currently used as a parameter
for diagnosis. Its use is based mainly on clinical
grounds and ICA are measured only when the
diagnosis of diabetes type is uncertain.
In research settings ICA, GADA or IA-2A are
useful parameters for assessing the extent of 
β-cell autoimmunity and for correlation analysis
with other data. This modus operandi should
clearly be extended to clinical settings too. The
paper by Decochez et al. clearly showed the per-
sistence of islet cell antigen-related antibodies in
type 1 diabetic patients after diagnosis. This
finding suggests the presence of β-cell antigens
as well as β-cell function, as testified by residual 
C-peptide secretion several years after diagnosis.
Intervention at diagnosis with intensive insulin
therapy and possible adjuvant therapy such as
nicotinamide is aimed not only at controlling 
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